TAG:
gene sequencing
Exome Sequencing Next “Big Thing” for Diagnosis
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
April 2, 2012 “Intelligence: Late Breaking Lab News”
Like a tenacious bulldog, Roche Holding AG continues its determined effort to acquire Illumina, Inc., the company that makes gene sequencing systems. Last week, Roche increased its offer from $44.50 per share to $51 per share for Illumina stock. That raises the price…
Roche Offers $5.7 Billion To Acquire Illumina Inc.
CEO SUMMARY: Once again, Roche is hunting for gene sequencing and gene analysis technology that can support its goal of being a world leader in gene-based therapeutics and clinical lab testing that utilizes gene tests and molecular diagnostics. Last week, Roche launched a hostile stock te…
Considering Full versus Partial Adoption of Digital Pathology
CEO SUMMARY: Digital pathology is considered to be one of the more disruptive technologies now finding acceptance in anatomic pathology. Since founding Aperio Technologies, Inc., of Vista, California, in 1999, President Dirk G. Soenksen, M.S., M.B.A., has been in the forefront of this imp…
May 23, 2011 “Intelligence: Late Breaking Lab News”
The first sequencing of the whole human genome back in 2000 unleashed a tidal wave of research and development. Recently, Fast Company Magazine quantified the dollar impact of the Human Genome Project and now says it totals $800 billion! Their reporter communicates this so succinctly that TH…
Whole Genome Sequencing: Is It Ready for Prime Time?
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…
Clinical Labs and Whole Human Gene Sequencing
CLINICAL LABORATORY ADMINISTRATORS AND SENIOR EXECUTIVES would be well advised to pay close attention to our lead story about the whole human genome sequence collaboration just announced by the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQue…
August 23, 2010 “Intelligence: Late Breaking Lab News”
With the goal of developing biomarkers useful in diagnosing a variety of cancers, Pathwork Diagnostics, Inc., and Novartis AG announced a research partnership on July 30. It is an early example of a collaboration between a diagnostics company and a pharmaceutical com…
June 21, 2010 “Intelligence: Late Breaking Lab News”
Early in June, exactly 96 customers of 23andMe, Inc., were notified that they had received the wrong genetic test results. It was particularly bad timing, since the company had just been sent a letter from the FDA asserting its authority to regulate genetic testing. Bloggers reported…
2009’s Top Ten Lab Stories Reflect Some Good, Bad
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with l…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.